Microbiological Screening Of Malignant Otitis Externa Patients Presenting at Sohag University Hospitals

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorSohag University

About this trial

This is a prospective study to identify the bacterial and fungal organisms causing Malignant Otitis Externa (MOE) in patients presenting to Sohag University Hospitals. Ear swabs will be collected from patients diagnosed with MOE and sent to the microbiology lab for culture and sensitivity testing. The goal is to determine the most common pathogens and their antibiotic resistance patterns to help doctors choose the best treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients clinically diagnosed with MOE based on severe otalgia, external auditory canal inflammation ± granulation tissue.

Patients with risk factors such as DM, Immunocompromised patients.

Disqualifiers

Post-operative ear cases (recent ear surgery).

Patients with external auditory canal tumors.

Patient refusal

Trial population

Patients diagnosed with Malignant Otitis Externa presenting to the ENT department at Sohag University Hospitals

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • ear swab and susceptibility testing

    Other intervention

    For all enrolled patients, an ear swab will be collected for bacterial and fungal culture and antibiotic susceptibility testing. This is a diagnostic procedure only and is not a therapeutic intervention. No drugs are administered as part of this study.

Treatment groups

40 Participants
are divided into 1 treatment group
Group A: MOE patients1 intervention

Trial outcomes

Primary outcomes

1

Number and percentage of bacterial and fungal isolates resistant to each antibiotic tested at enrollment

Measure: Antibiotic susceptibility testing will be performed on all isolates obtained from patients with Malignant Otitis Externa according to CLSI guidelines. Metric: Count and percentage of resistant isolates for each antibiotic.

Time frame
At time of enrollment, from July 2026 to July 2027

Secondary outcomes

1

Number and percentage of microbial isolates with antibiotic and antifungal resistance at enrollment

Microbial isolates including bacteria and fungi will be obtained from patients with Malignant Otitis Externa. Antimicrobial susceptibility testing will be performed for bacteria and antifungal susceptibility testing for fungi according to CLSI guidelines. Metric: Count and percentage of resistant isolates reported separately for bacterial and fungal organisms for each antimicrobial agent tested.

Time frame
At time of enrollment, from July 2026 to July 2027

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.